mercredi 20 novembre 2019

Onco Actu du 20 novembre 2019


1. BIOLOGIE



Epigenetic Changes Pinpointed as the Cause of Some GISTs [NCI]











Cell death or cancer growth: a question of cohesion [DKFZ]











3.1.1 PRÉVENTION - TABAC - E-CIGS



American Cancer Society Updates Position on Electronic Cigarettes [ACS]











Trump’s stalling on flavored vape ban draws blowback — and fears of lasting damage to American health [STAT]











American Medical Association Calls for Removal of the Main Competitors to Cigarettes from the Market [The Rest of the Story]










2 More States Sue Juul Over the Marketing of Its Vaping Products [NY Times]











AMA calls for total ban on all vaping products not approved by FDA [AMA]










Influential U.S. doctors group calls for ban on vaping products [Reuters]











4.12 BIOPSIES LIQUIDES



Exact Sciences Marker Panel Detects Early Liver Cancer With Triple Sensitivity of Current Biomarker [Genome Web]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Double Mutations in PIK3CA Gene Increase Patient Sensitivity to Targeted Therapies, Study Finds [Genome Web]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Milestone reached in new leukemia drug [Cold Spring Harbor Lab]











Arthritis drugs could prevent fatal spread of breast cancer [The Telegrah]











Study Suggests Repurposed Drugs Might Treat Aggressive Lung Cancer [NIH Director's Blog]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Trispecific antibodies offer a third way forward for anticancer immunotherapy [Nature]










5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals [Pharmafile]











5.2 PHARMA



Myovant's oral prostate cancer drug matches incumbent in phase 3 [Fierce Biotech]











Myovant to Seek FDA OK on Pill to Treat Advanced Prostate Cancer [Xconomy]










Myovant to submit lead drug for prostate cancer approval after Phase 3 results [Biopharma Dive]











Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer [Myovant]











As uterine race with AbbVie heats up, Myovant eyes FDA approval with trial results from prostate cancer [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



31 biopharmas at high risk of bankruptcy in 2020 [Biopharma Dive]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma [Genmab]











FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma [ESMO]











6.1 OBSERVATION



Anal cancer rates and mortality have risen dramatically among Americans [UT Health]










Anal cancer rates and deaths are climbing in the US, study says [CNN]











6.7 DMP, BIG DATA & APPLIS



Google health-data scandal spooks researchers [Nature]










Tools to help healthcare providers deliver better care [Google]











6.7.1 IA/BIOINFORMATIQUE



London AI upstart, which counts Novartis as a customer, can teach your computer to read [EndPoints]